|
Feb 11
|
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
|
|
Feb 11
|
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
|
|
Feb 10
|
Why Axsome Therapeutics Stock Is Skyrocketing Today
|
|
Feb 10
|
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
|
|
Feb 10
|
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
|
|
Dec 31
|
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
|
|
Dec 30
|
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation
|
|
Dec 30
|
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
|
|
Sep 29
|
1 Under-the-Radar Biotech Stock to Buy and Hold
|
|
Aug 27
|
Axsome Therapeutics to Participate in Investor Conferences in September
|
|
Jul 30
|
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit
|
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 19
|
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week
|
|
Jun 11
|
Why Axsome Therapeutics Stock Is Sinking Today
|
|
May 18
|
3 Monster Stocks in the Making You Can Buy Right Now
|
|
May 13
|
15 Most Depressed States in the US
|
|
May 11
|
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
|
|
May 11
|
Prediction: These 2 Growth Stocks Could Triple By 2030
|
|
May 9
|
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
|